Accelerate Fund IV has invested $2.7 million in Northernmost, a Canadian medical device company developing the innovative NoMo Kidney Pump to improve kidney organ preservation and transplantation outcomes.

Information on the Target

Accelerate Fund IV has recently invested in Northernmost, a pioneering medical device company based in Edmonton, Alberta. Founded by Ron Mills and Daniel Salamon, Northernmost focuses on developing innovative solutions for organ preservation, specifically through their groundbreaking NoMo™ Kidney Pump. This next-generation perfusion machine aims to enhance the preservation and transportation of donor kidneys, thus improving transplant outcomes significantly.

The NoMo Kidney Pump stands out due to its compact design, which allows for continuous circulation of preservation fluid through the kidney. This innovation not only reduces organ damage during transport but also extends the potential distance over which kidneys can be shipped. Given that kidneys are the most frequently transplanted organ, addressing their preservation will increase the availability of viable donor kidneys and potentially boost success rates in transplant surgeries.

Industry Overview in Canada

The organ transplant industry in Canada is critically important, as it plays a vital role in saving lives by facilitating the transfer of viable organs from donors to recipients. The need for improved organ preservation technologie